Table 3.

Outcomes of patients treated with caplacizumab as initial treatment vs patients not treated with caplacizumab

	patients with iTTP treated with caplacizumab as initial treatment (n = 44)	patients with iTTP not treated with caplacizumab (n = 78)	P
Clinical remission	42/44 (95.5%)	73/78 (93.6%)	.6501
Exacerbation	2/44 (4.5%)	16/78 (20.5%)	.023
Refractoriness∗	2/44 (4.5%)	11/78 (14.1%)	.042
Death	2/44 (4.5%)	6/78 (7.7%)	.567

^∗The 2 patients who were refractory to treatment were those who died, although they were different from the other 2 who had an exacerbation.